Retinoid related molecules: new promises against lung and breast cancer

Bibliography

• SPORN MB, ROBERTS AB, GOODMAN OS: The Retinoids:Biology, Chemistry and Medicine (Second Edition). Raven Press, Ltd, New York, NY (1994).
   Google Scholar
• CASTAIGNE S, CHOMIENNE C, DANIEL MT et al.:All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Blood (1990) 76:1704–1709.
   PubMed Web of Science ®Google Scholar
• HUANG ME, YE YC, CHEN SR et al.: Use of all-trans-ret-inoic acid in the treatment of acute promyelocytic leu-kemia. Blood (1988) 72:567–572.
   PubMed Web of Science ®Google Scholar
• PFAHL M, APFEL R, BENDIK I et al.: Nuclear retinoid re-ceptors and their mechanism of action. In: Vitamins and Hormones Vol. 49. Litwac G (Ed.), Academic Press, Inc., Orlando, FL, USA (1994):327–382.
   Google Scholar
• MANGELSDORF DJ, UMESONO K, EVANS R: The retinoid receptors. In: The Retinoids (Second Edition), Sporn MB, Roberts AB, Goodman DS (Eds.), Academic Press, Inc., Or-lando, FL, USA (1994):319–349.
   Google Scholar
• CHAMBON P: The retinoid signaling pathway: molecu-lar and genetic analyses. Semin. Cell Biol. (1994) 5:115–125.
   PubMedGoogle Scholar
• LA VISTA-PICARD N, HOBBS PD, PFAHL M et al.: Thereceptor-DNA complex determines the retinoid re-sponse: a mechanism for the diversafication of theligand signal. Mol Cell Biol (1996) 16:4137–4146.
   PubMed Web of Science ®Google Scholar
• •A new principle is demonstrated and it is shown that the af-finity of the retinoid receptor is modulated by the DNA se-quence to which the receptor binds to.
   Google Scholar
• LEHMANN JM, JONG L, FANJUL A et al.: Retinoids selec-tive for retinoid X receptor response pathways. Science (1992) 258:1944–1946.
   PubMed Web of Science ®Google Scholar
• •This is the first description and demonstration of principle that RXR selective ligands can be obtained (the basis for new anti-breast cancer and type II diabetes drug candidates).
   Google Scholar
• ZHANG XK, LEHMANN J, HOFFMANN B et al.: Homodi-mer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature (1992) 358:587–591.
   PubMed Web of Science ®Google Scholar
• YANGYEN HF, ZHANG XK, GRAUPNER G eta].: Antago-nism between retinoic acid receptors and AP-1: impli-cation for tumor promotion and inflammation. New Biol. (1991) 3:1206–1219.
   Google Scholar
• PFAHL M: Nuclear receptor/AP-1 interaction. Endocri-nol. Rev. (1993) 14(5):651–658.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, LERNHARD JM, WILLSON TM et al.: A prosta-glandin J2 metabolite binds peroxisome proliferator-activated receptor y and promotes adipocyte differen-tiation. Cell (1995) 83:813–819.
   PubMed Web of Science ®Google Scholar
• FORMAN BM, TONTONOZ P, CHEN J et al.: 15-deoxy-Al2,14-prostaglandin J2 is a ligand for the adi-pocyte determination factor PPARy. Cell (1995) 83:803–812.
   PubMed Web of Science ®Google Scholar
• FORMAN BM, GOODE E, CHEN J et al.: Identification of a nuclear receptor that is activated by farnesol metabo-lites. Cell (1995) 81:687–693.
   PubMed Web of Science ®Google Scholar
• KLIEWER SA, MOORE JT, WADE L et al.: An orphan nu-clear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell (1998) 92:1–20.
   Web of Science ®Google Scholar
• GRAUPNER G, MALLE G, MAIGNAN J et al.: 6'-Substituted naphthalene-2-carboxylic acid analogs, a new class of retinoic acid receptor subtype-specific ligand. Bio-chem. Biophys. Res. Commun. (1991) 179:1554–1561.
   PubMed Web of Science ®Google Scholar
• LEHMANN JM, DAWSON MI, HOBBS PD et al.: Identifica-tion of retinoids with nuclear receptor subtype-selective activities. Cancer Res. (1991) 51:4804–4809.
   PubMed Web of Science ®Google Scholar
• FANJUL AN, DELTA D, PIEROTTI MA eta].: A novel class of retinoids with selective anti-AP-1 activity exhibit anti-proliferative activity. Nature (1994) 372:107–111.
   Google Scholar
• •This is the first and only manuscript that describes a new class of retinoids called anti-AP-1 selective retinoids, a group of synthetic compounds that lack most classical retinoid ac-tivities, but which can still down-regulate the expression of genes controlled by the transcription factor, AP-1. These types of compounds are likely to show favourable toxicity profiles.
   Google Scholar
• LU XP, FANJUL AN, PICARD N et al.: Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nature Medicine. (1997) 3:686–690.
   PubMed Web of Science ®Google Scholar
• ••A novel RRM with strong anti-lung cancer activity and littletoxicity in vivo is described. The molecule, MX335, is dis-cussed extensively.
   Google Scholar
• MUKHERJEE R, DAVIES PJA, CROMBIE DL et al: Sensitiza-tion of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (1997) 386:407–410.
   PubMed Web of Science ®Google Scholar
• ••It is demonstrated that RXR selective compounds, also calledrexinoids, have potential as anti-type II diabetes drugs.
   Google Scholar
• PIEDRAFITA FJ, PFAHL M: Retinoid-induced apoptosisand Spl cleavage occur independently of transcrip-tion and require caspase activation. Mol. Cell Biol. (1997) 17:6348–6358.
   PubMed Web of Science ®Google Scholar
• ••The mechanisms of apoptosis induction by novel RRMs is in-vestigated. A novel retinoid signalling mechanism appears to exist that functions independently of transcription.
   Google Scholar
• JORDAN VC: Studies on the estrogen receptor in breastcancer-20 years as a target for the treatment and prevention of cancer. Third Annual William I. McGuire Memorial Lecture. Cancer Res. Treat. (1995) 36:267–285.
   Web of Science ®Google Scholar
• FISHER B, DIGNAM J, BRYANT J et al: Five versus morethan five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. (1996) 88:1529–1542.
   PubMed Web of Science ®Google Scholar
• FISHER B: Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J. Clin. On-col. (1996) 14:1027–1039.
   PubMed Web of Science ®Google Scholar
• JORDAN VC: A current view of tamoxifen for the treat-ment and prevention of breast cancer. Fourteenth Gad-dum Memorial Lecture. Br. J. Pharmacol. (1993) 110:507–517.
   Google Scholar
• MILLER VA, BENEDETTI FM, RIGAS JR et al.: Initial clini-cal trial of a selective retinoid X receptor ligand, LGD1069../ Gun. Oncol. (1997) 15:790–795.
   Google Scholar
• •Initial clinical trial results with the RXR selective ligand, LGD1069.
   Google Scholar
• BISCHOFF ED, GOTTARDIS MM, MOON TE et al.: Beyondtamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGREITN) causes complete regression of mammary carcinoma. Cancer Res. (1998) 58:479–484.
   PubMed Web of Science ®Google Scholar
• ••The RXR selective ligand, LGD1069, is more potent in a ratbreast cancer model than tamoxifen (and also may have fewer side effects)
   Google Scholar
• HSU JY, PFAHL M: ET-1 expression and growth inhibi-tion of prostate cancer cells: a retinoid target with novel specificity. Mol. Cell Biol. (1998). (Submitted.)
   Google Scholar